You are here
Celladon Receives Patent for Heart Failure Drug
Mydicar is a genetically targeted enzyme replacement therapy intended to restore levels of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a), a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage heart failure, resulting in deficient heart function. With Mydicar, the SERCA2a gene is delivered using recombinant adeno-associated virus as the vector.
Mydicar is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. The drug is synergistic and additive across current heart failure treatments, such as angiontensin-converting enzyme (ACE) inhibitors, beta-blockers, spironolactone/diuretics, and biventricular pacing devices.
Read the news release, available here.